07:29 AM EDT, 08/07/2025 (MT Newswires) -- Insmed ( INSM ) reported a Q2 net loss Thursday of $1.70 per diluted share, narrowing from a loss of $1.94 a year earlier.

Analysts polled by FactSet expected a loss of $1.29.

Arikayce product revenue for the quarter ended June 30 was $107.4 million, compared with $90.3 million a year earlier.

Analysts surveyed by FactSet expected $104.1 million.

For 2025, the company continues to expect global Arikayce product revenue of $405 million to $425 million. Analysts polled by FactSet expect $466.6 million.

Insmed ( INSM ) shares were down 4.4% in recent premarket activity.